Emerald Mutual Fund Advisers Trust’s Corvus Pharmaceuticals CRVS Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.86M	Buy	526,389 +67,136	+15%	+$932K	0.28%	105
2026 Q1	$6.72M	Buy	+459,253	New	+$7.33M	0.33%	100

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's CRVS Position: Q2 2026 in Review

Emerald Mutual Fund Advisers Trust increased its Corvus Pharmaceuticals (CRVS) stake by 15% in Q2 2026, buying an estimated $932K and bringing the position to 526,389 shares worth $7.86M. The position accounts for 0.28% of the portfolio, ranked #105.

Emerald Mutual Fund Advisers Trust first reported a position in CRVS in Q1 2026 and has held it in 2 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

Emerald Mutual Fund Advisers Trust held 526,389 shares of Corvus Pharmaceuticals worth $7.86M as of Q2 2026.
Emerald Mutual Fund Advisers Trust bought 67,136 Corvus Pharmaceuticals shares in Q2 2026, an estimated $932K.
Corvus Pharmaceuticals made up 0.28% of Emerald Mutual Fund Advisers Trust's portfolio in Q2 2026, its #105 holding.
Emerald Mutual Fund Advisers Trust first reported a position in Corvus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q2 2026, filed 5 Aug 2026.